Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Class 2 Response - Adenovirus

Our STN:  BL 125296/0

Teva Women’s Health, Inc.
Attention:  Valerie Mulligan                                          
425 Privet Road
PO Box 1005
Horsham, PA  19044

Dear Mr. Mulligan:

We have received your September 13, 2010, resubmission to your biologics license application for Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, for the immunization against acute respiratory disease caused by ADV 4 and 7 on September 14, 2010.

We consider this a complete, Class 2 response to our action letter.  Therefore, the user fee goal date is March 16, 2011.

If you have any questions, please contact the Regulatory Project Manager,
Ms. Helen Gemignani, at (301) 827-3070.

Sincerely yours,


Wellington Sun, M.D.
Division of Vaccines and
Related Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Page Last Updated: 04/13/2011
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English